Agenus Tangible Book Value per Share

What does Agenus do? Agenus, Inc. develops immuno-oncology therapies focused on engaging the immune system to treat cancer. The company's product portfolio includes antibody discovery platforms like Retrocyte Display, SECANT yeast display, and phage display technologies for human antibody production. Its antibody candidate programs feature checkpoint modulator (CPM) programs, while vaccine programs consist of Prophage, AutoSynVax, and PhosPhoSynVax, supported by the QS-21 Stimulon adjuvant. Agenus targets clinical-stage development for cancer and infectious disease treatments, leveraging its proprietary platforms to advance therapies through its discovery pipeline. The company's revenue streams come from its clinical-stage immuno-oncology programs, with products such as the QS-21 Stimulon adjuvant used in vaccine development. Agenus commercializes its technologies through partnerships and licensing agreements for its antibody platforms and vaccine candidates. Its target segments include pharmaceutical companies seeking advanced immuno-oncology solutions and vaccine developers requiring adjuvant technology. The firm's focus on checkpoint modulators and heat shock protein-based vaccines positions it to serve the oncology and infectious disease markets through its proprietary platforms and programs. Agenus develops therapies using antibody discovery platforms including Retrocyte Display, SECANT yeast display, and phage display. Its vaccine candidates like Prophage, AutoSynVax, and PhosPhoSynVax are supported by the QS-21 Stimulon adjuvant. The company's CPM programs and HSP-based vaccine platforms drive its clinical development pipeline. Agenus targets pharmaceutical firms and vaccine developers as key customers for its immuno-oncology technologies and adjuvant solutions, focusing on cancer and infectious disease applications. Agenus is one of the most popular companies on Eulerpool.